Pinealon
Tripeptide (Glu-Asp-Arg). Khavinson-lineage 'short peptide' bioregulator marketed for cognitive function.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Russian Academy of Sciences (Khavinson) framework treats short peptides as gene-expression regulators in target tissues — Pinealon for brain, Vilon for thymus, etc. Russian clinical reports describe cognitive benefit in elderly subjects. Western mechanistic and clinical replication is absent.
All efficacy literature is Russian-academy-lineage. Treat as Epitalon-class speculation. Identity and quality verification poor in grey market.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
Pinealon — primary mechanism: tripeptide (glu-asp-arg). khavinson-lineage 'short peptide' bioregulator marketed for cognitive function.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 30-100 mg · daily, oral or subcutaneous, in cycles
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Russian dietary supplement; not FDA-evaluated